Clarity Pharmaceuticals (CU6) - Cash for Copper
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh). Clarity have recently...
532 Views
Clarity Pharmaceuticals (CU6) - More SECuRE than Ever
Clarity have provided the market with new positive data from both their diagnostic (COBRA) and therapeutic (SECuRE) PSMA prostate cancer (PC)...
448 Views
Clarity Pharmaceuticals (CU6) - More Positive Data SECuREd
Clarity have announced further positive data from their ongoing Phase I/IIa theranostic trial in mCRPC with 64Cu-/67Cu-SAR-bisPSMA.
396 Views
Clarity Pharmaceuticals (CU6) - Lesion Size: A New Potential Differentiator
Clarity have released further data from their Phase II COBRA trial evaluating their 64Cu-SAR- bisPSMA PET diagnostic agent in suspected biochemical...
418 Views
Clarity Pharmaceuticals (CU6) - The COBRA Strikes…with a Lot of Venom
Clarity have released results from their Phase II COBRA trial, evaluating their 64Cu-SAR-bisPSMA PET agent in prostate cancer (PCa) patients with...
533 Views